News & Updates
Filter by Specialty:
Fructose from fruit juice, SSBs tied to higher liver fat content
The consumption of fructose from fruit juice and sugar sweetened beverages (SSBs), but not from fruit, is associated with higher intrahepatic lipid (IHL) content, according to data from a cross-sectional study presented at EASD 2021.
Fructose from fruit juice, SSBs tied to higher liver fat content
13 Oct 2021
Gene mutations may provide clues for liver cancer survival
Recent research has found that mutations in the human EZH2 and CCND1 genes may be potential novel biomarkers for liver cancer. The tumour mutation burden (TMB) also appears to be an important prognostic factor and affects patient survival.
Gene mutations may provide clues for liver cancer survival
13 Oct 2021
Mediterranean diet may brighten outlook in polyvascular atherosclerotic disease
Adherence to a Mediterranean dietary pattern among polyvascular atherosclerotic disease (PAD) patients leads to improvements in inflammatory and metabolic status, which may potentially translate into better long-term cardiovascular outcomes, according to a study.
Mediterranean diet may brighten outlook in polyvascular atherosclerotic disease
13 Oct 2021
Older age, CRP portend deaths in COVID-19 patients with diabetes
Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.
Older age, CRP portend deaths in COVID-19 patients with diabetes
13 Oct 2021
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
While patients with haematological malignancies (HM) are able to mount a persistent antibody response against the spike (S) protein of the SARS-CoV-2 virus, early treatment with rituximab completely abolishes such response, a recent study has found. These findings could help inform coronavirus disease 2019 (COVID-19) vaccination policies for patients with HMs.
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
12 Oct 2021
Ticagrelor after abbreviated DAPT minimizes bleeding while preserving efficacy in ACS
Monotherapy with ticagrelor after a month-long course of dual antiplatelet (DAPT) with ticagrelor plus aspirin works to reduce the risk of bleeding without compromising ischaemic outcomes among patients with acute coronary syndrome (ACS) as compared with guideline-recommended treatment with 12-month DAPT followed by aspirin monotherapy, according to data from the GLOBAL LEADERS trial.